CE
2717
CE-marked
Class IIa
PSG
Validated against polysomnography
QMS
ISO 13485 quality system
HDS
Certified health data hosting
AHI ≥15 events/h vs PSG.
AHI ≥15 events/h vs PSG.
Mean bias 0.03 events/h
491 enrolled · 9 centres · 3 countries
No PSG-severe patient was classified as normal in EASY study
With Class IIa CE marking, the Apneal report is not only a screening alert: it can be used by a healthcare professional as part of their clinical evaluation. The CE marking applies to the whole European market; integration into each diagnostic pathway depends on national health-system rules, and a confirmatory exam may be required depending on the clinical situation.
Apneal among the AI devices reviewed by BSI, our notified body
Sleep-related breathing disorders, including sleep apnea, affect over 900 million people globally — a major public health issue.
More than 80% of cases are never identified, leaving millions exposed to untreated cardiovascular and metabolic risk and persistent fatigue.
Untreated sleep disorders increase the risk of life-threatening conditions, such as cardiovascular disease, by up to five times.
Polysomnography and home polygraphy require dedicated equipment, delivery logistics and a healthcare professional to set up — barriers for patients and health systems alike.
Apneal captures the same physiological signals through the sensors already inside the patient’s smartphone, and analyses them with AI to produce a clinical report that physicians can use in their diagnostic evaluation.
No device to ship, retrieve, clean or maintain. No accessory. No electronic waste. The test can start the very night of the consultation.
The smartphone is placed on the chest, over pyjamas, held by adhesive and cohesive bands available at any pharmacy — with airplane mode activated. The app guides each step, and the night is spent naturally, in one's own bed, in any position.
The sensors already inside the phone record breathing movements, breathing sounds and snoring, and heart rate — the same cardiorespiratory signals a sleep test measures, captured differently. Over 95% of smartphones are compatible; nothing else is needed.
Apneal's AI counts the breathing events of the night — the apnea–hypopnea index — estimates sleep time and tells central events from obstructive ones. A clear night summary is available in the app, and a full report — in the same format as a standard sleep test — is shared with the prescribing physician, who makes the diagnosis.
Apneal enters the care pathway as diagnostic support: fewer barriers for patients, faster orientation for clinicians, and sleep-centre resources kept for the cases that need them. The medical decision stays with the physician — every time.
A guided, wire-free test in their own bed, starting the night of the consultation, with a personalised night summary the next morning. Fewer hospital nights, faster access to care.
A polygraphy-style report — AHI, sleep time, central vs obstructive events — to prioritise referrals, replace home polygraphy for standard patients and keep polysomnography for complex cases. The diagnosis remains yours.
A reliable first-line test for sleep apnea, with integrated clinical questionnaires, to quickly identify the patients who need specialist referral — without any equipment to stock.
Multi-night recording without hardware logistics: capture night-to-night variability, support treatment titration and long-term follow-up, and keep patients engaged.
In clinical practice, we still lack simple ways to access objective sleep data. Making this assessment more accessible can help clinicians better understand their patients’ symptoms, support the diagnostic evaluation and guide the next steps of care.
Apneal® is a Class IIa medical device (CE marking) manufactured by Mitral SAS, intended for sleep apnea diagnostic support. It is a regulated health product; read the instructions for use carefully. The diagnosis is made by a healthcare professional.
Privacy Policy – Legal Notice – © 2025 Apneal — All rights reserved